Dyadic International (DYAI) Free Cash Flow Growth (3y) (2021 - 2026)
Powered by 
Analysis
Dyadic International (DYAI) Free Cash Flow Growth (3y) (2021 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.70 Bn | 192.71 Bn | 7.24 Bn | -3.13% |
| 2 | Gilead Sciences | 180.18 Bn | 177.00 Bn | 6.22 Bn | 16.01% |
| 3 | Vertex Pharmaceuticals | 131.45 Bn | 123.60 Bn | 2.84 Bn | -1.95% |
| 4 | Regeneron Pharmaceuticals | 81.94 Bn | 73.95 Bn | 3.93 Bn | -20.15% |
| 5 | Argenx Se | 60.60 Bn | 55.42 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.81 Bn | 48.67 Bn | 52.00 Mn | 21.16% |
| 7 | Alnylam Pharmaceuticals | 33.46 Bn | 30.15 Bn | 992.69 Mn | 80.69% |
| 8 | Biogen | 31.82 Bn | 30.54 Bn | 1.96 Bn | -0.65% |
| 9 | Roivant Sciences | 29.10 Bn | 29.10 Bn | 1.16 Mn | - |
| 10 | Dyadic International | 18.44 Mn | 10.48 Mn | - | 3.53% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 3.53% |
| Dec 31, 2025 | -1.72% |
| Sep 30, 2025 | -1.41% |
| Jun 30, 2025 | 58.16% |
| Mar 31, 2025 | 11.89% |
| Dec 31, 2024 | 35.83% |
| Sep 30, 2024 | 64.07% |
| Jun 30, 2024 | -26.01% |
| Mar 31, 2024 | 91.64% |
| Dec 31, 2023 | 10.48% |
| Sep 30, 2023 | -12.35% |
| Jun 30, 2023 | 4.63% |
| Mar 31, 2023 | -3.09% |
| Dec 31, 2022 | -6.28% |
| Sep 30, 2022 | -4.85% |
| Jun 30, 2022 | -7.44% |
| Mar 31, 2022 | -26.46% |
| Dec 31, 2021 | -28.95% |
| Sep 30, 2021 | -75.53% |
| Jun 30, 2021 | 935.51% |